乳酸菌拓扑异构酶parC基因突变与其耐氟喹诺酮类药的相关性  

The correlation between the mutation of lactic acid bacteria parC gene of topoisomerase IV and its resistance to fluoroquinolones

作　　者：韦婉[1] 李少英[1] 李淑芬[2] 

机构地区：[1]内蒙古农业大学食品科学与工程学院,呼和浩特010018 [2]内蒙古农业大学生命科学学院,呼和浩特010018

出　　处：《中国抗生素杂志》2014年第1期19-23,共5页Chinese Journal of Antibiotics

基　　金：内蒙古高等学校科学研究项目:"耐喹诺酮类双歧杆菌Ⅱ型拓扑异构酶基因QRDR突变的研究"(NJ09059);国家自然科学基金项目:"益生菌Ⅱ型拓扑异构酶基因QRDR变化与耐药性的相关性"(31060014)

摘　　要：目的探讨parC基因的改变与乳酸菌耐氟喹诺酮类抗生素的相关性。方法采用纸片法和打孔法测定15株菌对诺氟沙星和氧氟沙星的敏感性。PCR扩增检测parC基因氟喹诺酮类耐药决定区相关片段并测序,比对敏感菌株和耐药菌株的测序结果,分析突变位点。结果 NN、NN2、NN3等7株为耐药菌株,4对引物PCR扩增检测parC基因,耐药菌株和对照菌株比较,没有发现parC基因的变化。结论乳酸菌对氟喹诺酮类药物的耐药性与其拓扑异构酶ⅣparC基因的突变无关。Objective To investigate the correlation between parC gene alterations and lactic acid bacteria resistance to fluoroquinolones. Methods Disk diffusion and beating holes methods are used to measure the sensitivity of 15 strains to norfloxacin and ofloxacin. PCR amplify the fluoroquinolones resistance determining region ofparC gene. Single nucleotide polymorphisms were found by the sequences alignment of the sensitive and resistant strains. Results 7 resistant strains included NN, NN2, NN3, etc. Four pairs of primers were used to amplify parC genes. The sequence results indicate that there are no sequence difference between fluoroquinolones resistant strains and control strains. Conelusion The resistance of lactic acid bacteria to fluoroquinolone have no relationship with the topoisomerase IV parC gene mutation.

关 键 词：乳酸菌 氟喹诺酮类药物 拓扑异构酶Ⅳ PARC 

分 类 号：R378[医药卫生—病原生物学] TS201.3[医药卫生—基础医学]